Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24596657 | 0.86 | ALDH1A1 (0.38) | CYP1A1CYP1A2FYNAHRKDM4E | |
| SCHEMBL26543253 | 0.85 | — | — | |
| SCHEMBL24245548 | 0.85 | ABCG2 (0.34) | ABCG2CYP1A1CYP1A2FYNMAPK3 | |
| SCHEMBL19986142 | 0.85 | MAPT (0.33) | KDM4EALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL18026430 | 0.85 | MAPT (0.37) | CYP1A1CYP1A2KDM4EALDH1A1MAPT | |
| SCHEMBL23129154 | 0.85 | ALDH1A1 (0.37) | CYP1A1CYP1A2KDM4EALDH1A1MAPT | |
| SCHEMBL22133345 | 0.84 | L3MBTL1 (0.40) | KDM4EALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL22211857 | 0.84 | ALDH1A1 (0.35) | KDM4EALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL19986143 | 0.83 | MEN1 (0.32) | MAPTKMT2ATDP1 | |
| SCHEMBL20315766 | 0.83 | ALDH1A1 (0.43) | KDM4EALDH1A1MAPTHPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230134350-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | LUMINESCENCE TECHNOLOGY CORP. (TW) | 2023-05-04 | — | — | US | disclosed |
| US-20230134350-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | LUMINESCENCE TECHNOLOGY CORP. (TW) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230134350-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | OR10J3, ODC1, OTC | ABCG2 1431/4885CYP1A1 772/4885CYP1A2 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.